In contrast, MMS typically predominantly manifests as a secondary vasculopathy within monogenic disease frameworks, where primary genetic defects (e.g., JAG1 in Alagille syndrome, NF1 in RASopathies) disrupt cerebrovascular homeostasis through pathway-specific mechanisms. This evidence concerns the gene JAG1 and Alagille syndrome.